We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression.
- Authors
Inomata, Minehiko; Tanaka, Hiroaki; Tokui, Kotaro; Taka, Chihiro; Okazawa, Seisuke; Kambara, Kenta; Imanishi, Shingo; Yamada, Toru; Miwa, Toshiro; Hayashi, Ryuji; Tobe, Kazuyuki
- Abstract
Introduction: Nivolumab has been reported to be more effective in the subset of non-squamous non-small cell lung cancer (NSCLC) patients with tumors harboring wild-type epidermal growth factor receptor (EGFR) and/or expressing programmed death ligand-1 (PD-L1). However, it is unclear whether PD-L1 expression influences the efficacy of nivolumab in patients with EGFR-mutated NSCLC. Therefore, tumor PD-L1 expression was evaluated in five patients with EGFR-mutated NSCLC who had been treated with nivolumab. Methods: We have identified patients with NSCLC harboring EGFR gene mutation retrospectively out of a group of 23 consecutive patients treated with nivolumab at our hospital between January 2016 and March 2017. The tumors of patients with EGFR-mutated NSCLC who had received nivolumab treatment based on clinical judgment were analyzed retrospectively. Tumor PD-L1 expression was evaluated by measurement of the tumor proportion score (TPS) using a rabbit antihuman PD-L1 antibody (clone 22C3). Results: Three patients received the treatment with nivolumab as second line treatment, and two patients received the treatment as third line treatment. One out of five patients had a response with treatment with nivolumab and that was the only patient with a positive PD-L1 expression (TPS of 80-90%). Conclusion: The results of the present study suggest that evaluation of tumor PD-L1 expression might be useful for predicting the efficacy of nivolumab, even in patients with EGFR-mutated NSCLC.
- Subjects
NON-small-cell lung carcinoma; CANCER treatment; IMMUNOTHERAPY; ANTINEOPLASTIC agents; EPIDERMAL growth factor receptors
- Publication
Oncology & Therapy, 2017, Vol 5, Issue 2, p181
- ISSN
2366-1070
- Publication type
Article
- DOI
10.1007/s40487-017-0053-3